ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES
First Claim
1. An antiviral pharmaceutical composition comprising a therapeutically effective amount of at least one antiviral oligonucleotide at least 20 nucleotides in length, wherein said oligonucleotide comprises at least 19 phosphorothioated linkages, does not comprise a CpG motif, does not have a compliment in the influenza A genome sequence and the antiviral activity of said oligonucleotide occurs principally by a non-sequence complimentary mode of action, and said target virus is influenza virus;
- and a pharmaceutically acceptable carrier.
1 Assignment
0 Petitions
Accused Products
Abstract
Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.
70 Citations
27 Claims
-
1. An antiviral pharmaceutical composition comprising a therapeutically effective amount of at least one antiviral oligonucleotide at least 20 nucleotides in length, wherein said oligonucleotide comprises at least 19 phosphorothioated linkages, does not comprise a CpG motif, does not have a compliment in the influenza A genome sequence and the antiviral activity of said oligonucleotide occurs principally by a non-sequence complimentary mode of action, and said target virus is influenza virus;
- and a pharmaceutically acceptable carrier.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)
-
27. A kit comprising at least one anti-viral oligonucleotide or anti-viral oligonucleotide formulation in a labeled package, wherein said oligonucleotide is at least 20 nucleotides in length, wherein said oligonucleotide comprises at least 19 phosphorothioate linkages, does not comprise a CpG motif, does not have a complement in the influenza A genome, wherein the anti-viral activity of said oligonucleotide occurs principally by a non sequence complementary mode of action, and the label on said package indicates that said anti-viral oligonucleotide can be used against a target virus, and wherein and said target virus is influenza virus.
Specification